Scientific Staff Profiles

This page allows you to read information about people engaged in research at CAMH. You can search for researchers using the name or keyword search engine below.

Dr. Tony P. George Clinical Director, Schizophrenia Program Endowed Chair in Addiction Psychiatry,U of T Centre for Addiction and Mental Health 250 College Street, Suite 734 Toronto, Ontario M5T 1R8 (416) 535-8501 ext. 4544 tony_george@camh.net Dr. Tony George is the Clinical Director for the Schizophrenia Program at CAMH. He is also the Endowed Chair in Addiction Psychiatry and a Professor in the Department of Psychiatry at the University of Toronto. Search again?
Areas of Research Dr. George is an expert in the pharmacology of drugs of abuse, co-morbid substance abuse and serious mental illness. His research focuses on the cognitive neuroscience of addictions and treatment of tobacco addictions in special populations. Dr. George's work involves preclinical studies in animals, human laboratories and clinical trials to build the knowledge base and translate research findings into better tools for clinicians. Dr. George is also collaborating with other scientists to fully understand all the elements that influence mental illness and addictions and to determine which comes first, a psychiatric disorder or an addiction.
Publications George, TP, Sacco, KA, Vessicchio, JC, Weinberger, AH, Shytle, RD (2008). Nicotinic Receptor Antagonist Augmentation of SSRI-Refractory Major Depressive Disorder: A Preliminary Trial. J. Clin. Psychopharmacol. 28: 340-344. George, TP, Weinberger, AH (2008). Monoamine Oxidase Inhibition as Tobacco Pharmacotherapy. Clin. Pharmacol. Therap. 83: 619-621. George, T.P., Vessicchio, J.C., Sacco, K.A., Creeden, C.L., Dudas, M.M., Allen, T.A., Weinberger, A.H., Hitsman, B., Jatlow, P.I. (2008). A Double-Blind, Randomized, Placebo-Controlled Trial of Sustained-Release Bupropion Combined with Transdermal Nicotine Patch for Smoking Cessation in Schizophrenia. Biol. Psychiatry. 63: 1092-1096. LeFoll, B., George, TP (2007). Treatment of tobacco dependence: integrating recent progress into practice. Can. Med. Assoc. J. 177: 1373-1380. Gershon Grand, RB, Hwang, S, Han, J, George, TP, Brody, AL (2007). Short-term Naturalistic Treatment Outcomes in Cigarette Smokers with Substance Abuse and/or Mental Illness. J. Clin. Psychiatry. 68: 892-898. Weinberger, AH, Sacco, KA, Termine, A, Vessicchio, JC, Jatlow, PI, George, TP (2007). Effects of Acute Abstinence and Reinstatement on Biochemical and Psychological Indices of Cigarette Smoking in Schizophrenia. Schizophr. Res. 91: 217-225. George, TP (2007). Alcohol Use and Misuse. Can. Med. Assoc. J. 176: 621-622. George, TP, Termine, A, Sacco, KA, Allen, TM, Reutenauer, E, Vessicchio, JC, Duncan, EJ (2006). A Preliminary Study of the Effects of Cigarette Smoking on Prepulse Inhibition in Schizophrenia: Involvement of Nicotinic Receptor Mechanisms, Schizophr. Res., 87: 307-315. Kleber, HD, Weiss, RD, Anton, RF, Jr., George, TP, Greenfield, SF, Kosten, TR, O'Brien, CP, Rounsaville, BJ, Strain, EC, Ziedonis, DM, Hennessey, G, Connery, H (2006). American Psychiatric Association. Clinical Practice Guidelines for the Treatment of Patients with Substance Use Disorders, 2nd edition. Am. J. Psychiatry. 163 (8S): 5-82. Sacco, KA, Termine, A, Seyal, AA, Dudas, MM, Vessicchio, JC, Krishnan-Sarin, S, Jatlow, PI, Wexler, BE, George, TP (2005). Effects of Cigarette Smoking on Spatial Working Memory and Attentional Deficits in Schizophrenia: Involvement of Nicotinic Receptor Mechanisms. Arch. Gen. Psychiatry, 62: 649-659 Kalman, D, Morissette, SB, George, TP. (2005). Co-morbidity of Smoking in Psychiatric and Substance Use Disorders. Am J. Addictions. 14: 106-123. Fonder, MA, Sacco, KA, Termine, A, Boland, BS, Seyal, AA, Dudas, MM, Vessicchio, JC, George, TP (2005). Smoking Cue-Reactivity in Schizophrenia: Effects of a Nicotinic Receptor Antagonist. Biol. Psychiatry. 57: 802-808. Sacco, KA, Bannon, KL, George, TP (2004). Nicotinic Receptor Mechanisms in Normal States and Neuropsychiatric Disease. J. Psychopharmacol. 18: 457-474. George, TP, O'Malley, SS (2004). Current Pharmacological Treatments for Nicotine Dependence. Trends Pharmacol. Sci. 25: 42-48. George, TP, Vessicchio, JC, Termine, A, Jatlow, PI, Kosten, TR, O'Malley, SS (2003). A Preliminary Placebo-Controlled Trial of Selegiline for Smoking Cessation. Biol. Psychiatry. 53: 136-143. George, TP, Vessicchio, JC, Termine, A, Bregartner, TA, Feingold, A, Rounsaville, BJ and Kosten, TR (2002). A Placebo-Controlled Trial of Bupropion for Smoking Cessation in Schizophrenia. Biol. Psychiatry. 52: 53-61. George, TP, Vessicchio, JC, Termine, A, Sahady, DM, Head, CA, Pepper, WT, Kosten, TR and Wexler, BE (2002). Effects of Smoking Abstinence on Visuospatial Working Memory Function in Schizophrenia. Neuropsychopharmacology. 26: 75-85. George, TP, Ziedonis, DM, Feingold, A, Pepper, WT, Satterburg, CA, Winkel, J, Rounsaville, BJ and Kosten, TR (2000). Nicotine Transdermal Patch and Atypical Antipsychotic Medications for Smoking Cessation in Schizophrenia. Am. J. Psychiatry. 157: 1835-1842.
Search again?

• Print